Menu Search
Equities

Joinn Laboratories China Co Ltd

6127:HKG.HZ

Joinn Laboratories China Co Ltd

Actions
  • Price (HKD)9.86
  • Today's Change-0.66 / -6.27%
  • Shares traded1.76m
  • 1 Year change-35.30%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 03:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.

  • Revenue in HKD (TTM)2.40bn
  • Net income in HKD147.97m
  • Incorporated1998
  • Employees2.59k
  • Location
    Joinn Laboratories China Co LtdA5 Rongjing East StreetEconomic-Technological Development AreaBEIJING 100176ChinaCHN
  • Phone+86 1 067869582
  • Fax+86 1 067869966
  • Websitehttps://www.joinnlabs.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.